Silo Pharma’s Sponsored Research Agreement with Columbia Could Yield a New Alzheimer’s Disease Treatment
November 3rd, 2021
Psychedelics, Top Story
Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet, despite significant investment in clinical trials, the FDA has only approved two types of medications to treat cognitive symptoms.
iHealthcareAnalyst reckons that the global market for AD treatments will reach $25 billion by 2027, representing a staggering 17.5% compound annual growth rate. Moreover, if a therapeutic successfully halts or reverses AD, the potential market could become much larger given that AD care costs exceed $200 billion per year in the U.S. alone.
Most clinical trials focus on the amyloid and tau hypotheses, which blame brain plaques and tau proteins for the disease. Unfortunately, several large Phase III clinical trials focused on these areas have failed. The good news is that there’s a new crop of research focused on alternative therapeutics to halt or slow the progression of the disease.
Let’s take a look at cutting-edge research out of Columbia University and the development-stage biopharmaceutical company with an option to license the results.
Combination Therapeutics with Ketamine
Silo Pharma Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on psychedelic therapeutics, recently entered a sponsored research agreement with Columbia University that could revolutionize the treatment of Alzheimer’s disease and other diseases related to memory loss or cognitive aging processes.
Dr. Christine Ann Denny, Associate Professor of Clinical Neurobiological at Columbia University’s Irving Medical Center, and her team are researching the molecular mechanisms underlying learning and memory. In particular, the team is pioneering research into whether drug combinations that incorporate ketamine might halt or reverse AD and related diseases.
Dr. Denny at her research lab at Columbia University. Source: Columbia University
Under the terms of the sponsored research agreement, Silo Pharma has an option to license certain assets that are currently under development, including Alzheimer’s disease-related inventions. With Big Pharma pouring billions into clinical trials in the space, a successful research outcome could create tremendous value for shareholders.
Following in Spravato’s Footsteps
Ketamine has become a breakthrough treatment for depression and suicidal ideations seemingly overnight. For example, Spravato (esketamine) became the first approved medicine to mitigate depressive symptoms within 24 hours. By comparison, conventional antidepressants take days or weeks to take effect with mixed results.
In the same way, ketamine-based therapeutics could revolutionize Alzheimer’s disease treatments. Memantine, a non-competitive NMDA receptor agonist with a similar pharmacological profile to ketamine, is already one of the most prescribed and investigated drugs for AD patients. However, ketamine has been largely ignored despite its unique potential to treat AD.
For example, memantine exhibits some antidepressant effects, but it has failed to produce the rapid antidepressant effect of ketamine. As a result, it stands to reason that ketamine’s antidepressant and procognitive effects aren’t entirely shared with memantine. Indeed, researchers point out several pathways that ketamine uniquely employs to combat AD, potentially enhancing treatments.
Alzheimer’s disease is a massive problem affecting populations worldwide, making it an enormous multi-billion dollar market.
Silo Pharma Inc.’s (OTCQB: SILO) recent sponsored research agreement with Columbia University targeting AD could be transformative for shareholders. If successful, the company has the option to acquire a new class of blockbuster drugs developed by the Columbia University team.
In addition to its AD research, the company has two drug candidates, two homing peptides for CNS and arthritis/inflammation, as well as two topical psychedelics with patented Zpod technology. With diversification across multiple medical conditions, shareholders benefit from greater diversification and long-term upside potential.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.